Results 221 to 230 of about 10,738 (252)
Some of the next articles are maybe not open access.
Mesalamine-induced granulomatous hepatitis
The American Journal of Gastroenterology, 1999A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata.
Francis Salamon +4 more
openaire +3 more sources
Gastroenterology Nursing, 1992
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire +2 more sources
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire +2 more sources
Gastroenterology Nursing, 1993
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire +2 more sources
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire +2 more sources
Designing a biocompatible hydrogel for the delivery of mesalamine
International Journal of Pharmaceutics, 2015A new design for nanocomposite hydrogels based on cross-linked chitosan for the delivery of mesalamine is presented. To enhance drug loading in chitosan, the mineral montmorillonite was incorporated into the matrix. The exfoliated silica montmorillonite nanosheets form interactions with both chitosan and mesalamine, which affect the hydrogel's drug ...
Havazelet Bianco-Peled, Lena Neufeld
openaire +2 more sources
Effectiveness of mesalamine and propolis in experimental colitis
Advances in Therapy, 2007This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid. The animals were randomly assigned to 5 groups: group 1, control, (n=8); group 2, colitis, received no treatment (n=8); group 3, colitis+mesalamine, 2 ...
Esin Atik +7 more
openaire +3 more sources
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Digestive and Liver DiseaseMedical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
Ferdinando, D'Amico +3 more
openaire +2 more sources
American Journal of Gastroenterology, 2014
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Moss, Alan +7 more
openaire +4 more sources
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Moss, Alan +7 more
openaire +4 more sources
Mesalamine-Induced Lung Disease
Archives of Internal Medicine, 1997Mesalamine (5-aminosalicylic acid), which is a component of sulfasalazine, has been used to treat inflammatory bowel diseases.1Most adverse pulmonary symptoms caused by treatment with sulfasalazine have been attributed to sulfapyridine.2Therefore, we thought it would be of interest to your readers to report a case involving an adverse pulmonary ...
M. T. Lázaro +2 more
openaire +2 more sources
Mesalamine derivatives in the treatment of Crohn's disease
Gastroenterology Clinics of North America, 2004The role of the aminosalicylates for induction therapy of mild moderate ulcerative colitis and as maintenance treatment has been substantiated by a large series of controlled clinical trials and confirmatory meta-analyses. Both sulfasalazine and newer derivatives are effective in preventing relapses.
Laura Harrell, Stephen B. Hanauer
openaire +3 more sources
Oral mesalamine for ulcerative colitis
ACP Journal Club, 1992Source Citation Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991 Sep 1;115:350-5.
openaire +2 more sources